P1033: A PHASE 2 STUDY OF THE LSD1 INHIBITOR IMG-7289 (BOMEDEMSTAT) FOR THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA (ET)

• F. Palandri,
• D. M. Ross,
• T. Cochrane,
• C. Tate,
• S. W. Lane,
• S. R. Larsen,
• A. T. Gerds,
• A. B. Halpern,
• J. Shortt,
• J. M. Rossetti,
• K. M. Pettit,
• J. Liang,
• A. Mead,
• M. Marchetti,
• A. Vannucchi,
• A. Wilson,
• J. R. Göthert,
• M. Hanna,
• A. Jones,
• J. Peppe,
• G. Natsoulis,
• T. McClure,
• W.-J. Hong,
• W. S. Stevenson,
• C. N. Harrison,
• M. Talpaz,
• N. Vianelli,
• H. Y. Rienhoff, Jr.

Affiliations

F. Palandri

1 Institute of Hematology “L. & A. Seràgnoli”, Sant’Orsola-Malpighi University Hospital, Bologna, Italy

D. M. Ross

2 Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide

T. Cochrane

3 Department of Haematology, Gold Coast University Hospital, Southport

C. Tate

3 Department of Haematology, Gold Coast University Hospital, Southport

S. W. Lane

4 QIMR Berghofer Medical Research Institute, Brisbane

S. R. Larsen

5 Institute of Haematology, Royal Prince Alfred Hospital, Sydney, Australia

A. T. Gerds

6 Cleveland Clinic Taussig Cancer Institute, Cleveland

A. B. Halpern

7 Department of Medicine, Division of Hematology, University of Washington, Seattle, United States of America

J. Shortt

8 Monash Haematology, Monash Health, Clayton, Australia

J. M. Rossetti

9 UPMC Hillman Cancer Center, Pittsburgh

K. M. Pettit

10 Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, United States of America

J. Liang

11 Middlemore Clinical Trials, Auckland, New Zealand

A. Mead

12 MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom

M. Marchetti

13 Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo, Alessandria

A. Vannucchi

14 University of Florence, AOU Careggi, CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Florence, Italy

A. Wilson

15 University College Hospital, NHS Foundation Trust, London, United Kingdom

J. R. Göthert

16 Department of Hematology, West German Cancer Center (WTZ), University Hospital Essen, Essen, Germany

M. Hanna

17 North Shore Hospital. Waitemata District Health Board, Auckland, New Zealand

A. Jones

18 Imago BioSciences, Inc., South San Francisco, United States of America

J. Peppe

18 Imago BioSciences, Inc., South San Francisco, United States of America

G. Natsoulis

18 Imago BioSciences, Inc., South San Francisco, United States of America

T. McClure

18 Imago BioSciences, Inc., South San Francisco, United States of America

W.-J. Hong

18 Imago BioSciences, Inc., South San Francisco, United States of America

W. S. Stevenson

19 Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney, Australia

C. N. Harrison

20 Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom

M. Talpaz

10 Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, United States of America

N. Vianelli

21 Institute of Hematology, “L. & A. Seragnoli”, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

H. Y. Rienhoff, Jr.

18 Imago BioSciences, Inc., South San Francisco, United States of America